Articles tagged with Cancer Patients
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
A patient with adenoid cystic carcinoma was successfully treated with step-and-shoot proton arc therapy at Corewell Health William Beaumont University Hospital. The treatment showed minimal side effects, including only light skin discoloration, and the patient remains cancer-free.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
Researchers at Tulane University identified a potential new way to treat idiopathic pulmonary fibrosis (IPF) using an FDA-approved cancer drug. The treatment works by blocking the CTLA4 protein, which blocks overactive T cells, allowing the immune system to clear out damaged cells that cause lung scarring.
The Colorectal Cancer Alliance is strengthening its commitment to Project Cure CRC, a nonprofit dedicated to ending the disease through innovative research and patient navigation. The organization has awarded three new grants and will present two poster sessions at the AACR Annual Meeting.
Researchers developed an AI algorithm based on the medical history of over half a million patients, enabling GPs to identify increased risk of lung cancer up to 4 months before diagnosis. This method may also offer early detection for other types of cancer and improved patient outcomes.
A study by Johns Hopkins Medicine found that older adults with cancer benefit equally from immunotherapy treatments as younger patients, with key differences in their immune responses and cells. Researchers hope to develop new therapies tailored to different age groups' needs and improve treatment success.
A survey of patients who underwent breast cancer screening mammograms found most support AI's role as a second reader, but concerns about data privacy and bias persisted. Demographic factors such as education and racial background played a significant role in shaping patient perceptions of AI.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
Researchers at MD Anderson Cancer Center have discovered that adding copper-loaded agents to radiotherapy can overcome radioresistance in preclinical models of thoracic cancer. A novel blood-based biomarker, OSMR, has also been identified in patients with acute myeloid leukemia (AML), which shows prognostic potential and can help ident...
A new combination therapy using cemiplimab and isatuximab has shown promising results in a phase 2 clinical trial for extranodal NK/T-cell lymphoma, with 51% of patients achieving complete response. The study validated genomic biomarkers and a prognostic model developed by the National Cancer Centre Singapore, offering potential for mo...
The Lung-MAP 3.0 trial introduces a simplified genomic screening process, allowing most patients to be matched to a targeted treatment sub-study based on prior testing results. This expansion increases access to investigational treatments for patients with advanced non-small cell lung cancer.
A new study found that a gene-based blood test can accurately predict skin cancer recurrence in stage III melanoma patients. The test measures circulating tumor DNA levels to identify those most likely to respond well to therapy.
The SNMMI Mars Shot Research Fund has awarded a $100,000 fellowship to Dr. Randy Ye for his research on FAPI PET imaging for detecting invasive lobular carcinoma. The study aims to assess the ability of FAPI PET and FDG PET to detect tumors and evaluate its impact on patient care.
A new inpatient onconephrology service has been established to care for patients with cancer and kidney disease, resulting in improved kidney recovery rates. The study found that patients treated by the dedicated service were more likely to have kidney recovery at discharge compared to those treated by general nephrology services.
University of Virginia researcher Natasha D. Sheybani has received a $5.5 million grant to advance her research on focused ultrasound technology for breast cancer immunotherapy. Her work aims to enhance the safety, effectiveness, and precision of immunotherapy drugs.
Researchers developed a saliva test that uses AI to identify genetic mutations in the DPYD gene, which can affect how well cancer patients respond to chemotherapy. The study found several new mutations that could lead to severe side effects from 5-fluorouracil, a widely used chemotherapy drug.
Researchers have shed light on how a new type of antibody treatment works against ovarian cancer by reactivating patients' immune cells. The study shows that MOv18 IgE reverses the suppression of immune cells and induces them to kill cancer cells, providing new insights into this therapy.
The Ontario Institute for Cancer Research (OICR) has launched a yearlong campaign showcasing the personal stories of cancer patients and researchers. The campaign aims to shine a spotlight on the community's achievements in cancer research. OICR brings together scientists, clinicians, and everyday Ontarians to solve cancer together.
Researchers at Cold Spring Harbor Laboratory have identified a connection between the brain and immune system responsible for cachexia-related apathy. By targeting specific neurons and immune system proteins, they hope to improve cancer patients' quality of life and tolerance for treatments.
Researchers found significant disparities in quality of care and outcomes for patients with metastatic pancreatic cancer. Patients with higher social vulnerability indices were less likely to receive guideline-concordant systemic therapy, palliative care, or survive over 12 months.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
A new clinical trial at the University of Miami Miller School of Medicine is testing a novel combination of immunotherapy drugs and an oncolytic virus to treat high-grade neuroendocrine cancer. The trial aims to find safe combination doses and compare effectiveness with standard-of-care treatment.
A new editorial in Oncotarget discusses how artificial intelligence can improve liver imaging by recognizing when it might be wrong. The approach, called 'uncertainty quantification,' helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look.
A UCLA study validates the predictive power of PROSTOX, a genetic test that uses microRNAs to identify patients at higher risk of developing long-lasting urinary side effects from radiation therapy. The test helps doctors and patients choose safer treatment options, reducing the burden of long-term complications.
A new study found that blocking an enzyme called HPGDS may be a way to improve melanoma treatment for patients who don't respond to immunotherapy. The enzyme promotes tumor growth and metastasis dissemination by blocking T-cell activity, but blocking it boosts the immune response.
The new tool has the potential to improve cancer survival rates and patient quality of life worldwide by allowing for more targeted and less invasive surgeries. Researchers are currently developing a fully functional prototype that can be trialled in large animal models before progressing to human clinical trials.
A Phase I trial demonstrates AFM13-NK cells are safe and highly effective in heavily pretreated patients with refractory CD30-positive lymphomas, achieving an overall response rate of 92.9% and complete response of 66.7%. The treatment was well-tolerated, with no cases of cytokine release syndrome or graft-versus-host disease.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
A new case report presents a highly unusual combination of two benign ovarian tumors: serous cystadenofibroma and collision lesions. Accurate preoperative diagnosis is critical for effective treatment planning, and this case emphasizes the need for personalized evaluation of each ovarian mass.
A federally funded study by Huntsman Cancer Institute found that 7% of Medicare patients with cancer cross state borders for treatment, with rates nearly double for rural patients. Telehealth can fill gaps in cancer treatment and reduce travel burdens, says senior author Tracy Onega.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
Researchers discovered that a high-fat diet activates mechanisms facilitating breast cancer metastasis by promoting platelet activation and fibronectin expression, creating a fertile breeding ground for tumor cells to take root. This study provides new insights into the relationship between obesity and breast cancer spread.
The NCCN 2025 Annual Conference showcased the critical impact of cancer research on improving lives. The conference featured new research, discussions on AI in oncology care, and strategies for ensuring high-quality, person-centered cancer care.
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
The University of Rochester's Wilmot Cancer Institute has been named the nation's 73rd designated cancer center by the National Cancer Institute. This prestigious designation recognizes the institute's excellence in cancer research, patient care, and community outreach.
A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.
A single-center retrospective study analyzed clinical data, imaging, histopathological manifestations, genetic testing results, and treatment effects in 48 WD patients. The study found age at diagnosis, K-F ring presence, and higher immunoglobulin G levels were associated with cirrhosis risk factors.
A study published in Plastic and Reconstructive Surgery reports that breast-conserving therapy, including radiation therapy, leads to progressive breast volume loss over time. Women with larger breasts experience greater total breast shrinkage, highlighting the need to discuss long-term changes in breast volume with patients.
Researchers at MD Anderson Cancer Center made several key discoveries, including the spatial organization of cancer-associated fibroblasts across various cancers and a study on treatment resistance in SMARCA4-mutant lung cancer. These findings highlight the importance of investigating cell populations in their spatial context to better...
Researchers developed a personalized app that tracks users' circadian rhythms and provides behavioral recommendations to reduce daily fatigue. The app, called Arcasync, was tested on 138 participants with breast, prostate, and blood cancer, resulting in decreased fatigue and improved quality of life.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
The FDA has approved cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors. The drug showed improved efficacy in reducing tumor growth and improving patient survival compared to placebo.
A new review highlights how breast cancer cells change their communication and growth patterns, helping tumors survive, spread, and resist treatment. The review explores disrupted signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, which can promote tumor progression and resistance to treatment.
A single-arm trial evaluated the safety and efficacy of first-line camrelizumab, apatinib, and chemotherapy in untreated extensive-stage small-cell lung cancer patients. The treatment demonstrated an ORR of 88.9% and median PFS and OS of 7.3 and 17.3 months, respectively.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
Patients with hormone receptor-positive and HER2-negative breast cancers face a higher risk of death from the cancer if they wait more than 42 days after diagnosis to have surgery. Delayed surgery increases the patient's risk exponentially, with risks of death increasing by 21%, 79%, and 183% at 60, 90, and 120 days, respectively.
A study published in the British Journal of General Practice found a significant link between chest x-ray referrals and earlier lung cancer diagnosis and better survival rates. Patients attending practices with high chest x-ray usage were more likely to be diagnosed at an earlier stage, leading to improved survival rates.
A simple urine test has shown promising results in detecting early-stage kidney cancer recurrence, with a high sensitivity and specificity rate. The GAGome test can accurately identify patients at risk of recurrence, potentially reducing the need for invasive scans and enabling faster treatment access.
A TB vaccination has been shown to boost the immune system of bladder cancer patients, reducing cancer recurrence rates by up to 75% in a small pilot study. The vaccine was well-tolerated with no side effects and showed promising results in improving patient outcomes.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
Researchers at Dana-Farber Cancer Institute have identified a potential targeted therapy, avapritinib, for pediatric high-grade gliomas. The treatment resulted in tumor reduction and clinical improvement in 3 out of 7 patients with this currently incurable form of brain cancer.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A comprehensive review of studies reveals that over 15% of caregivers of adult cancer patients suffer from post-traumatic stress disorder (PTSD). Caregivers with pre-existing mental health conditions and high caregiver burden are at greater risk. The study highlights the urgent need for proactive screening and support to prevent long-t...
Researchers found that detectable mutant KRAS circulating tumor DNA (ctDNA) indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma. The study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
This cohort study found that geographic access to cancer care is associated with guideline-recommended treatment for early-stage non–small cell lung cancer. Socially marginalized patients benefited from improved treatment outcomes and prognosis when accessing care in their local area.
Researchers developed an AI tool called Unfold AI to accurately estimate prostate tumor volume and identify patients likely to benefit from partial gland cryoablation. This approach shows promise in reducing treatment failures by over 70% and improving patient outcomes.
A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.